Literature DB >> 6726527

Patent ductus arteriosus in neonates with severe respiratory disease.

G G Dudell, W M Gersony.   

Abstract

Daily aortic contrast echo studies were carried out in 200 neonates with severe respiratory disease to determine the natural history of the ductus arteriosus during the first days of life and the effect of patency on subsequent morbidity and mortality. Decisions related to surgical or pharmacologic closure of a PDA were not based on the results of the contrast echo studies. The risk that intervention would be required was greater in infants weighing less than 1500 gm (P less than 0.005) and in patients in whom the ductus had not closed spontaneously by day 3 (P less than 0.001) regardless of birth weight. The clinical course in infants with a PDA on the third day of life revealed a lower survival rate (P less than 0.005), a greater requirement for prolonged respiratory support (P less than 0.005), and a higher incidence of bronchopulmonary dysplasia (P less than 0.005) in all birth weight categories. Ductal patency often was not associated with early clinical manifestations. No infant who had a negative echo study on the third day of life subsequently developed signs or symptoms of patent ductus arteriosus. We conclude that patency of the ductus arteriosus is a negative prognostic factor in the severely ill neonate with respiratory distress.

Entities:  

Mesh:

Year:  1984        PMID: 6726527     DOI: 10.1016/s0022-3476(84)80499-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

1.  Day case ligation of patent ductus arteriosus in preterm infants: a 10 year review.

Authors:  C R Satur; D R Walker; D F Dickinson
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

2.  Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants.

Authors:  B H Su; T Watanabe; M Shimizu; M Yanagisawa
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-07       Impact factor: 5.747

Review 3.  Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.

Authors:  Manoj N Malviya; Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

Review 4.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

5.  Color Doppler flow mapping of the patent ductus arteriosus in very low birthweight neonates: echocardiographic and clinical findings.

Authors:  D A Roberson; N H Silverman
Journal:  Pediatr Cardiol       Date:  1994 Sep-Oct       Impact factor: 1.655

Review 6.  The pharmacological treatment of patent ductus arteriosus. A review of the evidence.

Authors:  R J Barst; W M Gersony
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

7.  Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.

Authors:  J M Smyth; P S Collier; M Darwish; J S Millership; H L Halliday; S Petersen; J C McElnay
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

8.  Bronchopulmonary dysplasia in infants with respiratory distress syndrome in a developing country: a prospective single centre-based study.

Authors:  J Smith; S Kling; R P Gie; J van Zyl; G F Kirsten; E D Nel; J W Schneider
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

9.  Re-evaluation of the left atrial to aortic root ratio as a marker of patent ductus arteriosus.

Authors:  P Iyer; N Evans
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-03       Impact factor: 5.747

10.  Long-term morbidities associated with vocal cord paralysis after surgical closure of a patent ductus arteriosus in extremely low birth weight infants.

Authors:  J R Benjamin; P B Smith; C M Cotten; J Jaggers; R F Goldstein; W F Malcolm
Journal:  J Perinatol       Date:  2009-09-17       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.